Complement Decay Accelerating Factor, CD55
In addition to the above, colorectal tumours express CD55 which is a ligand that protects against complement-induced cell death and its overexpression is significantly associated with reduced survival.[212] An anti-idiotype vaccine against this epitope has shown encouraging results in that it can induce strong T and NK cell immune responses; however, early results suggesting clinical activity were not confirmed in a randomized study which used more advanced patients.[213] Studies in early stage disease would be more appropriate.
Aliment Pharmacol Ther. 2006;24(8):1163-1177. © 2006 Blackwell Publishing
Comments